Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Prostatic Neoplasms 32Metastatic Castration-resistant Prostate Cancer 4Kidney Neoplasms 3Prostatic Neoplasms, Castration-Resistant 2Carcinoma, Renal Cell 2Urogenital Neoplasms 1Thrombocytopenia 1Renal Insufficiency 1Prostatic Diseases 1Prostate Cancer Metastatic 1PSMA-positive Metastatic Castration Resistant Prostate Cancer (mCRPC) With Prior Exposure to One Prior ARPI Who Are Candidates for Taxane-based Chemotherapy 1Neoplasms by Site 1Neoplasms 1Metastatic Hormone Naive Prostate Cancer 1Metastatic Castration Resistant Prostate Cancer (mCRPC) 1Metastatic Castrate Resistant Prostate Cancer (mCRPC) 1Male Urogenital Diseases 1Liver Neoplasms 1High-Risk Localized Prostate Cancer 1Glioma 1Glioblastoma 1Genital Neoplasms, Male 1Disease 1Cytopenia 1Clear-cell metastatic renal cell carcinoma 1Carcinoma, Hepatocellular 1Carcinoma 1Astrocytoma 1Anemia 1

Interventions

Cyclophosphamide 3Dexamethasone 2Bortezomib 2veliparib 1pembrolizumab 1isatuximab 1gallium 68 PSMA-11 1Whole-Body Irradiation 1Taxes 1Standard of Care 1Pluvicto 1Paclitaxel 1Kidney Transplantation 1Health Information Exchange 1Eplerenone 1Carboplatin 1Calcium Dobesilate 1Blood Specimen Collection 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Renal Insufficiency × Pluvicto × 1 year × Clear all
NCT06004661 2026-03-06

Study of Lutetium (177Lu) Vipivotide Tetraxetan in mCRPC Participants With Moderately and Severely Impaired and With Normal Renal Function

Novartis

Phase 2 Recruiting
20 enrolled

Renal Insufficiency

Data powered by HemOnc (CC BY 4.0) Colophon âš¡